COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Date results information initially provided
Type of registration
Retrospectively registered

Titles & IDs
Public title
Resveratrol in the prevention of colorectal polyps
Scientific title
Resveratrol in the chemoprevention of colorectal neoplasia in people with high risk of colorectal cancer including carriers of Hereditary Non-polyposis Colorectal Cancer and their families, people who have had colorectal cancer and people who have had colorectal polyps
Secondary ID [1] 262290 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
high risk/familial risk of colorectal cancer 4613 0
Condition category
Condition code
Oral and Gastrointestinal 4912 4912 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Cancer 268128 268128 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Study type
Description of intervention(s) / exposure
This study will recruit 128 participants with a family history of colorectal cancer. The trial will be a randomized double blind, parallel design intervention after a 3-week washout period on a controlled diet. The controlled diet to be used was developed by Commonwealth Scientific and Industrial Research Organisation (CSIRO) Human Nutrition and this will be matched against known ingredients high in phenolic compounds. Blood and rectal biopsy samples will be collected for mucosal biomarkers measures. Randomized interventions will follow for 6 weeks with 100mL of dealcoholised red wine containing 50 mg resveratrol or a placebo consumed daily with the evening meal. Blood and biopsies will then be done again. The use of de-alcoholised wine will remove any risk of alcohol toxicity or cancer induction risk.
Intervention code [1] 4376 0
Comparator / control treatment
placebo - wine containing no resveratrol
Control group

Primary outcome [1] 5757 0
inflammation biomarkers (eg IL-6, CRP) , through rectal biopsies
Timepoint [1] 5757 0
at six weeks on conclusion of intervention
Primary outcome [2] 5758 0
expression of genes involved in normal structure and function of colorectal epithelium altered early in colorectal carcinogenesis, through rectal biopsies (Ki67 and TGF markers, apotosis markers Bax, Bc12 and bak, APC, beta-catenin and mismatch repair proteins)
Timepoint [2] 5758 0
at six weeks on conclusion of intervention
Primary outcome [3] 5759 0
colorectal epithelial crypt cell cycle events, through rectal biopsies
Timepoint [3] 5759 0
at six weeks on conclusion of intervention
Secondary outcome [1] 241713 0
local growth factor biomarkers, through rectal biopsies
Timepoint [1] 241713 0
at six weeks on conclusion of intervention

Key inclusion criteria
HNPCC carriers
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
pregnancy, co-morbidities

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
allocation is concealed. Allocation involves contacting the holder of the allocation schedule who is "off-site"
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation by using a randomization table created by a computer software (i.e., computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 4796 0
Government body
Name [1] 4796 0
Cancer Australia
Address [1] 4796 0
Ground Floor, 141 Penrhyn House, Block B, Bowes St, Woden ACT 2606
Country [1] 4796 0
Primary sponsor type
Melbourne Health
Royal Melbourne Hospital City Campus, Grattan St, Parkville. Vic 3050
Secondary sponsor category [1] 4329 0
Commercial sector/Industry
Name [1] 4329 0
Australian Wine Research Insititute
Address [1] 4329 0
PO Box 197, Glen Osmond SA 5064
Country [1] 4329 0

Ethics approval
Ethics application status
Ethics committee name [1] 6844 0
Melbourne Health Research Directorate
Ethics committee address [1] 6844 0
6 East, City Campus, Grattan St, Parkville Royal Melbourne Hospital, Vic. 3050
Ethics committee country [1] 6844 0
Date submitted for ethics approval [1] 6844 0
Approval date [1] 6844 0
Ethics approval number [1] 6844 0

Brief summary
This study aims to determine whether Resveratrol (contained in red wine) may prevent colorectal cancer in people with a family history of the disease.

Who is it for?
You can join this study if you are aged 18 years or more and are a carrier of hereditary non-polyposis colorectal cancer (HNPCC).

Trial details
Participants in this trial will eat a controlled diet developed by the CSIRO for a period of 3 weeks. They will then be randomly (by chance) divided into two groups. One group will consume 100ml of dealcoholised red wine containing 50 mg resveratrol daily with their evening meal for a period of 6 weeks. Participants in the other group will consume a placebo (sham) drink containing no resveratrol. Participants will not know which group they are in.

Blood and rectal biopsy samples will be taken from participants at the beginning and end of this study to assess any changes in markers associated with colorectal cancer.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 29498 0
Prof Finlay Macrae
Address 29498 0
Level 3 Centre,
Department of Colorectal Medicine & Genetics
Royal Melbourne Hosptial
Parkville, VIC, 3050
Country 29498 0
Phone 29498 0
03 9342 8995
Fax 29498 0
Email 29498 0
Contact person for public queries
Name 12745 0
Prof Finlay Macrae
Address 12745 0
Department of Colorectal Medicine & Genetics
Grattan St
The Royal Melbourne Hospital
Vic 3050
Country 12745 0
Phone 12745 0
+61 3 9342 7580
Fax 12745 0
+61 3 93427848
Email 12745 0
Contact person for scientific queries
Name 3673 0
Ms Creina Stockley
Address 3673 0
The Australian Wine Research Institute
PO Box 197, Glen Osmond SA 5064
Country 3673 0
Phone 3673 0
+61 8 83136612
Fax 3673 0
+61 8 83136601
Email 3673 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
It is not planned that IPD sharing will be available publically for this study.
What supporting documents are/will be available?
No other documents available
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary